Remove Healthcare Provider Remove Patients Remove Pharma Remove Pharmaceutical manufacturing
article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

Pharmaceutical manufacturers have submitted Citizen Petitions raising safety or efficacy concerns about proposed competing generic and biosimilar products, and such submissions often delay FDA approval of the proposed products while the FDA resolves the pending petitions. Conclusion.

article thumbnail

Diversity and inclusion in oncology clinical trials

Clarify Health

By enrolling participants with a wide range of baseline characteristics, study populations will more accurately reflect the patients likely to take the drug if it is approved. Cancer patients treated in clinical trials live substantially longer than those not treated in trials and benefit from lower hospital readmissions. 2] Figure 1.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Getting ahead of regulatory changes around PFAS in pharmaceutical packaging

Clarivate

Nitrosamines have garnered significant attention from the pharmaceutical industry due to their detection in commonly prescribed medications for conditions like type 2 diabetes, high blood pressure, and heartburn. [1] Manufacturers, healthcare providers, and consumers alike face the need to quickly adapt.

article thumbnail

Trends in Virtual Collaboration

Impetus Digital

Many of these will discuss the expanding role and capabilities of AI and machine learning in the Pharma space. The new way to engage KOLs at conferences: virtual Ambassador programs To start off the top-5, let’s take a look at how Pharma is shifting the way they engage key opinion leaders (KOLs) at medical congresses and conferences.